Skip to main content
TipRanks
Go Ultimate75% OFF

Top Page

PBPH

Portfolio Building Block World Pharma and Biotech Index ETF (PBPH)

Rating:70Neutral
Price Target:$31.00â–¼(-1.96% Downside)

PBPH, the Portfolio Building Block World Pharma and Biotech Index ETF, has a solid overall rating driven mainly by large positions in strong global pharma leaders like Merck, AstraZeneca, Johnson & Johnson, Novartis, and Gilead, all benefiting from robust financial performance, positive earnings outlooks, and healthy product pipelines. However, some key holdings such as Eli Lilly, AbbVie, Amgen, Roche, and Pfizer face valuation, leverage, or growth challenges that slightly weigh on the fund’s rating, and the main risk is its heavy concentration in the pharmaceutical and biotech sector, which can make performance more sensitive to industry-specific news and regulation.

Positive Factors
Strong Overall Year-to-Date PerformanceThe ETF has delivered strong gains so far this year, showing solid momentum in its pharma and biotech holdings.
Leading Global Pharma Companies in Top HoldingsMajor positions in well-known drug makers like Johnson & Johnson, Merck, Amgen, and others have shown strong or steady performance, helping support the fund’s returns.
Low Expense RatioThe fund’s relatively low annual fee means more of the investment gains can stay in investors’ pockets over time.
Negative Factors
High Concentration in a Few StocksA large share of the portfolio is tied up in a small number of companies, which increases the impact if any of these big holdings run into trouble.
Sector Concentration in Health CareWith most assets in the health care sector, the ETF is heavily exposed to industry-specific risks such as drug pricing pressures and regulatory changes.
Mixed Performance Among Top HoldingsWhile several key positions have performed well, some important holdings like AstraZeneca have shown weaker results, which can drag on overall returns.

PBPH vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%25%30%SPY+14.55%PBPH+26.21%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AUM
1.38B
Region
Developed Markets
Expense Ratio
0.13%
Beta
0.10
Issuer
Portfolio Building Block
Inception Date
Nov 24, 2025
Dividend Yield
0.07%
Asset Class
Equity
Index Tracked
BITA Global Pharma and Biotech Select Index - Benchmark TR Net

PBPH Summary

PBPH is an ETF that follows the BITA Global Pharma and Biotech Select Index, focusing on healthcare companies that earn most of their money from medicines and biotechnology. It holds many well-known names such as Eli Lilly and Johnson & Johnson, along with other major drug makers from the U.S. and abroad. Investors might consider PBPH if they want simple, one-click diversification across leading pharma and biotech firms and believe in long-term growth from new treatments and medical innovations. A key risk is that it is heavily concentrated in healthcare, so its value can rise or fall sharply with changes in drug pricing, regulation, or industry news.

How much will it cost me?

The Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) has an expense ratio of 0.13%, meaning you’ll pay $1.30 per year for every $1,000 invested. This is lower than average because it is a passively managed fund that tracks an index, which typically keeps costs down.

What would affect this ETF?

The PBPH ETF could benefit from increased global healthcare spending, advancements in biotechnology, and demand for innovative treatments, especially as its top holdings include leading pharmaceutical companies like Eli Lilly and Johnson & Johnson. However, it may face challenges from regulatory changes, patent expirations, or economic downturns that could reduce healthcare budgets and impact the performance of its holdings. Additionally, its focus on developed markets may limit exposure to growth opportunities in emerging economies.

PBPH Top 10 Holdings

PBPH is essentially a who’s who of global Big Pharma, with Eli Lilly, Johnson & Johnson, AbbVie, and Merck setting the tone. Lilly and AbbVie have been rising on the back of strong pipelines, while Merck and Amgen look like steady engines of growth rather than flashy high-fliers. AstraZeneca and Gilead add more punch, though their performance has been a bit more mixed, occasionally losing steam. With almost all exposure in large healthcare names across the U.S. and Europe, the fund is tightly focused on pharma and biotech heavyweights driving long-term returns.

PBPH top ten holdings
NameCompany NameWeight %Market ValueMarket CapYearly GainOverall Rating
LLYLLYEli Lilly & Co17.05%$227.86M$1.34T41.12%72Outperform
JNJJNJJohnson & Johnson9.51%$127.18M$682.52B46.35%78Outperform
ABBVABBVAbbVie7.34%$98.05M$520.47B27.01%66Neutral
MRKMRKMerck & Company5.12%$68.41M$362.27B59.00%80Outperform
RHHVFRHHVFRoche Holding AG――――73Outperform
AZNAZNAstraZeneca――――80Outperform
AMGNAMGNAmgen4.36%$58.34M$252.64B38.59%77Outperform
CH:NOVNCH:NOVNNovartis AG4.09%$54.61MCHF 245.70B26.78%80Outperform
GILDGILDGilead Sciences4.05%$54.09M$208.31B34.25%78Outperform
PFEPFEPfizer3.23%$43.18M$164.33B12.02%74Outperform

PBPH Technical Analysis

Technical Analysis SentimentPositive
Last Price31.62

Price Trends

50DMA29.30Positive
100DMA28.58Positive
200DMA27.14Positive

Market Momentum

MACD0.72Negative
RSI65.31Neutral
STOCH72.75Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PBPH, the sentiment is Positive. The current price of 31.62 is above the 20-day moving average (MA) of 30.72, above the 50-day MA of 29.30, and above the 200-day MA of 27.14, indicating a bullish trend. The MACD of 0.72 indicates Negative momentum. The RSI at 65.31 is Neutral, neither overbought nor oversold. The STOCH value of 72.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBPH.

PBPH Peer Comparison

Comparison Results

PBPH against its peer funds
NamePricePrice TargetAUMExpense RatioOverall Rating
PBPHPBPH$31.62$31.00(-1.96% Downside)$1.38B0.13%70Neutral
AIQAIQ$58.72$84.13(43.27% Upside)$9.55B0.68%64Neutral
BOTZBOTZ$31.23$40.91(30.98% Upside)$2.99B0.68%58Neutral
PBOGPBOG$36.16$40.48(11.94% Upside)$491.69M0.13%70Outperform
SRVRSRVR$28.43$37.03(30.25% Upside)$286.85M0.49%61Neutral
THNRTHNR$26.14$35.85(37.16% Upside)$5.27M0.59%64Neutral

Performance Comparison

0%20%40%PBPHAIQBOTZPBOGSRVRTHNRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
PBPH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
PBPHPortfolio Building Block World Pharma and Biotech Index ETF31.626.5726.21%
AIQGlobal X Artificial Intelligence & Technology ETF58.729.2618.73%
BOTZGlobal X Robotics & Artificial Intelligence ETF31.23-2.93-8.56%
PBOGPortfolio Building Block Integrated Oil and Gas and Exploration and Production Index ETF36.1611.3145.51%
SRVRPacer Benchmark Data & Infrastructure Real Estate SCTR ETF28.430.752.72%
THNRAmplify Weight Loss Drug & Treatment ETF26.141.556.32%
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.